TELA
TELA Bio, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 30 TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly a…
- May 12 ▼ TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly abov…
- Aug 10 ▼ TELA Bio reported Q2 2026 revenue of $19.3M, a 4% decline YoY, and a…
- Aug 14 to Aug 17 ▲ 2 days of insider buys: $18.8K by 1 insider, avg $0.6828
- Aug 31 TELA Bio announced a strategic cost reduction initiative including a…
- Aug 31 Leadership: TELA Bio Announces COO / CFO Transition and Strategic Cost…
- Sep 14 to Sep 17 ▲ 4 days of insider buys: $167.2K by 1 insider, avg $1.11
- Sep 15 ▼ Short interest jumps 43.2% to 550.8K
- Sep 25 Craig-Hallum initiates
- Oct 15 ▼ Short interest jumps 36.2% to 639.0K
- Nov 10 ▲ Earnings: TELA Q3 2026 Earnings: EPS $-0.13 (+20.5% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $186.0K at an average $1.05. No open-market sales. Price is 27% below their cost.
- InstitutionsMIXED
Q3 2026: 5 added (0 new), 4 trimmed or exited.
- AnalystsBULLISH
9 of 11 rate it Buy or better.
- EstimatesFALLING
Current-quarter EPS estimate −$0.150 → −$0.160 over 90 days. 4 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −9.3% to 579.6K shares. 5.1 days to cover, ≈1.3% of shares.
- TrendDOWNTREND
26% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | ADD | $94.0K |
| MORGAN STANLEY | DOUBLED | $80.5K |
| UBS Group AG | TRIM | $18.1K |
| CITIGROUP INC | ADD | $3.5K |
| JPMORGAN CHASE & CO | DOUBLED | $1.4K |
| Steward Partners Investment Advisory, LLC | TRIM | $1.1K |
| SIMPLEX TRADING, LLC | TRIM | $740.00 |
| BARCLAYS PLC | NEAR_EXIT | $7.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analysts| Date | Firm | Rating |
|---|---|---|
| Sep 25, 2026 | Craig-Hallum INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Plovanic William J. Director Oct 15, 2026 | AWARD | $16.2K |
Capper Joseph H Director Oct 15, 2026 | AWARD | $20.0K |
Capper Joseph H Director Sep 17, 2026 | BUY | $30.5K |
Capper Joseph H Director Sep 16, 2026 | BUY | $58.3K |
Capper Joseph H Director Sep 15, 2026 | BUY | $52.9K |
Capper Joseph H Director Sep 14, 2026 | BUY | $25.5K |
Getz Heather C Chief Executive Officer Aug 17, 2026 | BUY | $8.3K |
Getz Heather C Chief Executive Officer Aug 14, 2026 | BUY | $10.5K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.16 | -$0.21–-$0.13 | -1.3% | $20.0M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 3 press releases · 1 bullish · 4 bearish · 3 mixed · 9 neutral- NEUTRAL SC 13G/ANov 16, 2026
Stonepine Capital Management filed an amended Schedule 13G disclosing it has reduced its stake in TELA Bio to zero shares as of September 30, 2026, down from a prior position. This is a complete exit by a passive investor, which may signal a lack of conviction, though the filing remains routine…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 13, 2026
Nantahala Capital Management filed an amended Schedule 13G disclosing beneficial ownership of…
Monitor for any future conversion to a Schedule 13D, which would indicate activist intent. The 14.5% stake is large but passive; no immediate read-through.
- NEUTRAL SC 13G/ANov 13, 2026
North Run Capital, LP filed an amended Schedule 13G disclosing beneficial ownership of 3,528,296…
Monitor for any future conversion to a 13D filing or increase in stake that could signal activist intent. The passive certification limits near-term control-related actions.
- BEARISH S-3Nov 10, 2026
TELA Bio filed a new S-3 shelf registration statement to replace its expiring 2023 shelf…
Monitor for prospectus supplements that would trigger actual offerings under the shelf. The Baby Shelf limitation caps primary offerings at ~$17.3M over 12 months, limiting near-term dilution. The…
All TELA filing & press-release reports (20)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- SC 13G/A reportNov 13, 2026
- S-3 reportNov 10, 2026
- PRESS-RELEASE reportNov 10, 2026
- PRESS-RELEASE reportOct 27, 2026
- 8-K reportOct 6, 2026
- 8-K reportOct 5, 2026
- 8-K reportAug 31, 2026
- 8-K reportAug 10, 2026
- 3 reportJun 11, 2026
- 3 reportJun 11, 2026
- 3 reportJun 11, 2026
- 3 reportJun 11, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 8-K reportApr 30, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportMar 24, 2026
- PRESS-RELEASE reportMar 10, 2026